Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) shares traded -0.99% lower at $1.00 on Wall Street last session.
In accordance with the data, 1 analysts cover Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $7.00, we find $7.00. Given the previous closing price of $1.01, this indicates a potential upside of 593.07 percent. PIRS stock price is now -13.91% away from the 50-day moving average and -52.27% away from the 200-day moving average. The market capitalization of the company currently stands at $75.20M.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $7.00 as their price target over the next twelve months.
With the price target maintained at $5, Robert W. Baird recently Upgraded its rating from Neutral to Outperform for Pieris Pharmaceuticals Inc. (NASDAQ: PIRS)., while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Demuth Tim, Chief Medical Officer bought 6,000 shares of the company’s stock on May 13. The stock was bought for $10,260 at an average price of $1.71. Upon completion of the transaction, the Chief Medical Officer now directly owns 6,000 shares in the company, valued at $6000.0. A total of 9.86% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PIRS stock. A new stake in Pieris Pharmaceuticals Inc. shares was purchased by BRIDGEWAY CAPITAL MANAGEMENT, LLC during the first quarter worth $213,000. JACOBS LEVY EQUITY MANAGEMENT, INC invested $154,000 in shares of PIRS during the first quarter. In the first quarter, MAN GROUP PLC acquired a new stake in Pieris Pharmaceuticals Inc. valued at approximately $69,000. CORNERCAP INVESTMENT COUNSEL INC acquired a new stake in PIRS for approximately $39,000. WILLIAMS JONES WEALTH MANAGEMENT, LLC. purchased a new stake in PIRS valued at around $16,000 in the second quarter. In total, there are 85 active investors with 57.00% ownership of the company’s stock.
Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) opened at $1.0000 on Friday. During the past 12 months, Pieris Pharmaceuticals Inc. has had a low of $0.95 and a high of $4.08. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.30, and a quick ratio of 2.30. The fifty day moving average price for PIRS is $1.1532 and a two-hundred day moving average price translates $2.0836 for the stock.
The latest earnings results from Pieris Pharmaceuticals Inc. (NASDAQ: PIRS) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.14, missing analysts’ expectations of -$0.11 by -0.03. This compares to -$0.24 EPS in the same period last year. The company reported revenue of $5.37 million for the quarter, compared to $4.06 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 32.36 percent. For the current quarter, analysts expect PIRS to generate $2.26M in revenue.
Pieris Pharmaceuticals Inc.(PIRS) Company Profile
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.